Enfortumab Vedotin

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Bladder Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 1/2 · investigational in the US

Also approved (3)
CN
  • PADCEV (enfortumab vedotin) for adult patients with locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD-1/PD-L1 inhibitor
Product first approved 2024biospace.com
EU
  • Muscle invasive bladder cancer (MIBC) Padcev, in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. Unresectable or metastatic urothelial cancer Padcev, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. Locally...
Product first approved 2022EMA
JP
  • Treatment of unresectable urothelial carcinoma that has progressed after cancer chemotherapy
Product first approved 2021PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Bladder Cancer
NCT07346053 · Guliz Ozgun
2026-11 – 2032-12 · Advanced Bladder Cancer
What this study did
NCT07566156 · Astellas Pharma Global Development, Inc.
2026-05-11 – 2032-02-29 · Urothelial Cancer, Urinary Bladder Neoplasms
What this study did
Other / comorbidity
NCT04223856 · Astellas Pharma Global Development, Inc.
2020-03-30 – 2028-03-01 · Urothelial Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT07815665 · Summit Therapeutics
2026-09-10 – 2030-12-31 · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
What this study did
NCT04887870 · Mirati Therapeutics Inc.
2021-06-29 – 2025-09-25 · Advanced or Metastatic Solid Malignancies
What this study did
Phase 2 (42)
Bladder Cancer
NCT07663747 · The Netherlands Cancer Institute
2026-09-01 – 2032-04-01 · Urothelial Bladder Cancer
What this study did
NCT07908979 · Fox Chase Cancer Center
2026-10-16 – 2031-11-01 · Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
What this study did
NCT07475806 · Astellas Pharma Global Development, Inc.
2026-03-12 – 2031-04-30 · Muscle-invasive Bladder Cancer
What this study did
NCT07643519 · University of Florida
2026-12 – 2030-10 · Urothelial Carcinoma (UC)
What this study did
NCT06809140 · Matthew Galsky
2025-04-07 – 2029-11 · Muscle Invasive Bladder Urothelial Carcinoma
What this study did
NCT05656235 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-11-25 – 2029-06 · High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder
What this study did
NCT07647289 · Peking University Third Hospital
2025-04-15 – 2028-12 · Muscle-Invasive Bladder Cancer (MIBC)
What this study did
NCT07087860 · Mayo Clinic
2025-08-01 – 2028-08-07 · Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
What this study did
NCT05756569 · Emory University
2023-09-26 – 2027-12-16 · Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma
What this study did
NCT05879653 · Kyoto University Hospital
2023-10-01 – 2027-09-30 · Bladder Cancer
What this study did
NCT07332351 · University of Washington
2026-12-01 – 2027-07-01 · Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
What this study did
NCT05239624 · Memorial Sloan Kettering Cancer Center
2022-06-02 – 2027-06 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07822373 · University of Utah
2026-11 – 2035-11 · Muscle-invasive Bladder Urothelial Carcinoma
What this study did
NCT07863765 · Northwestern University
2027-05-05 – 2031-05-05 · Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable NUT Carcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Medullary Carcinoma
What this study did
NCT07110038 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-12-16 – 2030-11 · Penile Squamous Cell Carcinoma (PSCC)
What this study did
NCT03547973 · Gilead Sciences
2018-08-13 – 2030-04 · Metastatic Urothelial Cancer
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT07221942 · Fox Chase Cancer Center
2026-01-23 – 2029-09-03 · Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma
What this study did
NCT06553885 · H. Lee Moffitt Cancer Center and Research Institute
2025-04-01 – 2029-09 · Metastatic Colorectal Cancer, Hepatocellular Carcinoma
What this study did
NCT05923190 · Fox Chase Cancer Center
2023-06-14 – 2029-07-01 · Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
What this study did
NCT06302569 · Giuseppe Procopio
2025-05-30 – 2029-05 · Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma
What this study did
NCT07183319 · University of Oklahoma
2026-01-19 – 2029-03 · Urothelial Carcinoma
What this study did
NCT07374549 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-20 – 2028-12-01 · Advanced Urothelial Carcinoma
What this study did
NCT06041503 · National Cancer Institute (NCI)
2026-01-20 – 2028-10-01 · Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors
What this study did
NCT07347314 · National Cancer Center, Japan
2025-11-04 – 2028-09-30 · Advanced Small Bowel Adenocarcinoma
What this study did
NCT06145308 · Peking Union Medical College
2023-08-15 – 2028-07-10 · Salivary Gland Carcinoma, Precision Therapy
What this study did
NCT06104618 · Mayo Clinic
2023-12-21 – 2028-06-01 · Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma
What this study did
NCT06906822 · Grupo Español Multidisciplinar de Melanoma
2025-06-10 – 2028-06 · Melanoma
What this study did
NCT07139977 · William Bradley
2026-07-10 – 2028-05-31 · Endometrial Cancer
What this study did
NCT06311214 · National Cancer Institute (NCI)
2025-03-18 – 2028-03-31 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
What this study did
NCT06356155 · University of Michigan Rogel Cancer Center
2025-07-22 – 2028-03 · Urothelial Carcinoma
What this study did
NCT06904573 · Sun Yat-sen University
2025-01-01 – 2028-01-01 · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
What this study did
NCT05775471 · Jonsson Comprehensive Cancer Center
2024-06-24 – 2028-01-01 · Renal Pelvis and Ureter Urothelial Carcinoma
What this study did
NCT05868265 · Memorial Sloan Kettering Cancer Center
2023-06-02 – 2027-06-02 · Urothelial Carcinoma
What this study did
NCT06891560 · Memorial Sloan Kettering Cancer Center
2025-03-31 – 2027-03 · Adenoid Cystic Carcinoma
What this study did
NCT04754191 · University of Utah
2022-06-05 – 2027-01 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT05915351 · University of Kansas Medical Center
2023-06-30 – 2026-06-01 · Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
What this study did
NCT05097599 · Strata Oncology
2022-04-29 – 2024-06-12 · Cancer, Advanced Solid Tumor
What this study did
NCT03606174 · Mirati Therapeutics Inc.
2018-09-11 – 2022-08-22 · Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
What this study did
Phase 1/2 (15)
Bladder Cancer
NCT06305767 · Merck Sharp & Dohme LLC
2024-03-28 – 2031-10-20 · Bladder Cancer
What this study did
NCT06394570 · University of Texas Southwestern Medical Center
2024-09-10 – 2029-09-30 · Bladder Cancer
What this study did
NCT07667335 · Fred Hutchinson Cancer Center
2026-10-20 – 2029-07-16 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
What this study did
NCT04724018 · Dana-Farber Cancer Institute
2021-05-20 – 2028-05-01 · Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
What this study did
NCT06470282 · University of California, San Francisco
2025-03-31 – 2028-01-31 · Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
What this study did
NCT06434350 · M.D. Anderson Cancer Center
2024-10-10 – 2027-09-24 · Advanced Bladder Cancer
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07890714 · Daiichi Sankyo
2026-10-16 – 2030-01-31 · Urothelial Cancer, Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07287995 · Astellas Pharma Global Development, Inc.
2026-02-05 – 2029-06-30 · Locally Advanced or Metastatic Malignant Solid Tumors
What this study did
NCT07157956 · Convalife (Shanghai) Co., Ltd.
2025-09-10 – 2028-12-30 · Advanced Solid Tumor
What this study did
NCT07421700 · Pfizer
2026-03-11 – 2028-09-25 · Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
What this study did
NCT06483334 · Merck Sharp & Dohme LLC
2024-07-17 – 2028-03-31 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
What this study did
NCT05845814 · Merck Sharp & Dohme LLC
2023-06-23 – 2027-05-31 · Metastatic Urothelial Carcinoma, Urothelial Neoplasms
What this study did
Phase 1 (10)
Bladder Cancer
NCT07217496 · ImmunityBio, Inc.
2026-12 – 2032-01 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
What this study did
NCT04963153 · National Cancer Institute (NCI)
2022-07-07 – 2026-12-01 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
What this study did
NCT05014139 · Astellas Pharma Global Development, Inc.
2021-12-07 – 2025-09-22 · Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
What this study did
NCT05524545 · ALX Oncology Inc.
2022-11-02 – 2025-06-27 · Bladder Cancer, Urothelial Carcinoma
What this study did
Other / comorbidity
NCT04878029 · Emory University
2021-07-23 – 2028-12-21 · Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT07484022 · Generate Biomedicines
2026-06-08 – 2027-12 · Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
What this study did
NCT05614739 · Eli Lilly and Company
2023-01-12 – 2027-06 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
What this study did
NCT02091999 · Astellas Pharma Global Development, Inc.
2014-05-14 – 2022-12-07 · Metastatic Urothelial Cancer and Other Malignant Solid Tumors
What this study did
NCT03070990 · Astellas Pharma Inc
2017-04-24 – 2019-02-25 · Metastatic Urothelial Cancer
What this study did
NCT01409135 · Astellas Pharma Inc
2011-07-11 – 2015-04-27 · Tumors, Medical Oncology, Neoplasms
What this study did
Phase 4 (2)
Bladder Cancer
NCT06764095 · Mayo Clinic
2025-01-08 – 2032-01-01 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8
What this study did
Other / comorbidity
NCT06862219 · Astellas Pharma Global Development, Inc.
2025-06-21 – 2027-12-31 · Metastatic Urothelial Carcinoma
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07629700 · University of Florence
2026-09-01 – 2028-09-01 · Urothelial Carcinoma (UC), Peripheral Nerve Disease
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT07720284 · AstraZeneca
2026-07-16 – 2032-11-23 · High-risk Muscle Invasive Urothelial Carcinoma
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06493552 · Vasgene Therapeutics, Inc
2025-03-15 – 2034-08 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Enfortumab Vedotin: this drugApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug Envedotin
Phase 3(overall)
Antibody–drug conjugateNectin-4
not yet graded(overall)
No reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
Zelenectide Pevedotin
Phase 2(overall)
PeptideNectin-4
not yet graded(overall)
No reviewed efficacy summary in this indication
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(58 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Enfortumab Vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1Bladder CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04963153 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2026-12-16 · NCT05756569 · CT.gov ↗
What to watch
Phase 4Metastatic Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06862219 · CT.gov ↗
What to watch
2027 (23)
January 2027 (2)
Phase 2Advanced Urothelial Carcinoma, Probiotics, ImmunotherapyRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 2Renal Pelvis and Ureter Urothelial CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT05775471 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2027-03 · NCT06891560 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-04 · NCT07647289 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2027-04-23 · NCT06305767 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Metastatic Urothelial Carcinoma, Urothelial NeoplasmsActive not recruiting
Est. primary completion 2027-05-31 · NCT05845814 · CT.gov ↗
What to watch
June 2027 (6)
Phase 1Advanced Urothelial Cancer, Metastatic Urothelial CarcinomaRecruiting
Est. primary completion 2027-06 · NCT07484022 · CT.gov ↗
What to watch
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-06 · NCT05239624 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06 · NCT06906822 · CT.gov ↗
What to watch
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07332351 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06-02 · NCT05868265 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Early phase / not applicableUrothelial Carcinoma (UC), Peripheral Nerve DiseaseNot yet recruiting
Est. primary completion 2027-09-01 · NCT07629700 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2027-09-24 · NCT06434350 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary CarcinomaRecruiting
Est. primary completion 2027-10 · NCT06302569 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell TumorsRecruiting
Est. primary completion 2027-10-01 · NCT06041503 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-11 · NCT06809140 · CT.gov ↗
What to watch
Phase 1Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma …Recruiting
Est. primary completion 2027-11-13 · NCT04878029 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-11-30 · NCT07139977 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-11-30 · NCT07475806 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial CarcinomaRecruiting
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07217496 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2028-01-31 · NCT06470282 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT07183319 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT06356155 · CT.gov ↗
What to watch
Phase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Bladder CancerRecruiting
Est. primary completion 2028-06 · NCT05656235 · CT.gov ↗
What to watch
Phase 2Advanced Urothelial CarcinomaNot yet recruiting
Est. primary completion 2028-06-01 · NCT07374549 · CT.gov ↗
What to watch
Phase 2Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-01 · NCT06104618 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-07-01 · NCT05923190 · CT.gov ↗
What to watch
Phase 4Bladder CancerRecruiting
Est. primary completion 2028-07-01 · NCT06764095 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Bladder CancerRecruiting
Est. primary completion 2028-08-07 · NCT07087860 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial CarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT07221942 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2028-09-30 · NCT06394570 · CT.gov ↗
What to watch
Phase 2Advanced Small Bowel AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT07347314 · CT.gov ↗
What to watch
2029 (7)
February 2029 (1)
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07643519 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Penile Squamous Cell Carcinoma (PSCC)Recruiting
Est. primary completion 2029-05 · NCT07110038 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Locally Advanced or Metastatic Malignant Solid TumorsRecruiting
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2029-07-16 · NCT07667335 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Metastatic Colorectal Cancer, Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09 · NCT06553885 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07890714 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Bladder CancerRecruiting
Est. primary completion 2029-10-01 · NCT07908979 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2030-03-31 · NCT07566156 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Metastatic Urothelial CancerActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma …Not yet recruiting
Est. primary completion 2030-05-05 · NCT07863765 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2/3Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)Recruiting
Est. primary completion 2030-10-31 · NCT07815665 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Bladder CancerNot yet recruiting
Est. primary completion 2030-12 · NCT07346053 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2031-04-01 · NCT07663747 · CT.gov ↗
What to watch
July 2031 (1)
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2031-07-08 · NCT07232602 · CT.gov ↗
What to watch
2034 (1)
November 2034 (1)
Phase 2Muscle-invasive Bladder Urothelial CarcinomaNot yet recruiting
Est. primary completion 2034-11 · NCT07822373 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026ApprovalEuropean Commission expands Padcev approval to resectable MIBC
EU, EC · Source ↗
17 August 2026FDA action datePDUFA target action date August 17, 2026
US, FDA · Source ↗
7 July 2026Filing acceptedNMPA accepts BLA for Padcev plus Keytruda in muscle-invasive bladder cancer
CN, NMPA · Source ↗
20 April 2026Filing acceptedFDA accepts sBLA for perioperative PADCEV + Keytruda in MIBC
US, FDA · Source ↗
20 April 2026Priority reviewFDA grants Priority Review to PADCEV + Keytruda sBLA in MIBC
US, FDA · Source ↗
7 April 2026FDA action datePDUFA target action date set for April 7, 2026
US, FDA · Source ↗
17 December 2025Topline resultEV-304 Phase 3 interim topline results positive
22 October 2025Filing acceptedFDA accepts the PADCEV plus KEYTRUDA sBLA in MIBC and grants Priority Review
US, FDA · Astellas Pharma · Source ↗
18 October 2025Topline resultEV-303 Phase 3 positive topline results for PADCEV plus KEYTRUDA in MIBC
8 January 2025ApprovalNMPA approves PADCEV with KEYTRUDA for advanced urothelial cancer
CN, NMPA · Source ↗